{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-271105","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.778794+00:00","generated_at":"2026-06-23T00:06:11.316439+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Solid Biosciences effects 1-for-15 reverse stock split, reduces authorized shares to 60M","bullets":["1-for-15 reverse stock split effective Oct. 27, 2022; trading on split-adjusted basis begins Oct. 28.","Authorized common shares reduced from 300M to 60M (20M post-split then tripled per certificate amendment).","Stockholders approved the amendment at the June 7, 2022 annual meeting; no fractional shares, cash in lieu.","Outstanding options, warrants, and RSUs adjusted proportionally per their terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-271105","json":"https://secwatch.observer/filing/0001193125-22-271105.json","markdown":"https://secwatch.observer/filing/0001193125-22-271105.md","text":"https://secwatch.observer/filing/0001193125-22-271105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522271105/0001193125-22-271105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522271105/d346984d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:06:11.316439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}